世界の変形性関節痛用薬市場:成長動向・競争分析2020-2026

【英語タイトル】Global Medicine for Osteoarthritis Pain Industry Research Report, Growth Trends and Competitive Analysis 2020-2026

QYResearchが出版した調査資料(QYR20AP01436)・商品コード:QYR20AP01436
・発行会社(調査会社):QYResearch
・発行日:2020年3月25日(※2024年版があります。お問い合わせください)
・ページ数:142
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当リサーチレポートでは、変形性関節痛用薬の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、変形性関節痛用薬のグローバル市場動向、メーカー別競争状況、種類別市場規模(経口、注射、外用)、用途別市場規模(医療用、パーソナルケア用)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・変形性関節痛用薬の種類別市場2015-2026:経口、注射、外用
・変形性関節痛用薬の用途別市場2015-2026:医療用、パーソナルケア用
・変形性関節痛用薬の北米市場分析
・変形性関節痛用薬のアジア市場分析
・変形性関節痛用薬の中南米市場分析
・変形性関節痛用薬の中東・アフリカ市場分析
・関連企業情報:Pfizer、Johnson and Johnson、GlaxoSmithKline、Bayer、Eli Lilly、Novartis、Sanofi、Horizon Pharma、Abbott、Mylan、Daiichi Sankyo、TEVA、Almatica Pharma、Astellas Pharma、Tide Pharmaceutical、Iroko Pharmaceuticals、Hengrui Pharmaceutical、Abiogen Pharma
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

Medicine for Osteoarthritis Pain is to relieve pain, and cannot slow the progress of osteoarthritis.In 2019, the global Medicine for Osteoarthritis Pain market size was US$ xx million and is forecast to US$ xx million in 2026, growing at a CAGR of 5.7% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Medicine for Osteoarthritis Pain.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Medicine for Osteoarthritis Pain market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Medicine for Osteoarthritis Pain market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Medicine for Osteoarthritis Pain market. Readers of the report can become informed about current and future trends of the global Medicine for Osteoarthritis Pain market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Medicine for Osteoarthritis Pain markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Medicine for Osteoarthritis Pain market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Medicine for Osteoarthritis Pain market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Medicine for Osteoarthritis Pain market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Medicine for Osteoarthritis Pain market is segmented into
Oral
Injection
External

Market Segment by Application, the Medicine for Osteoarthritis Pain market is segmented into
Medical Care
Personal Care

This report includes the following manufacturers; we can also add the other companies as you want.
Pfizer
Johnson and Johnson
GlaxoSmithKline
Bayer
Eli Lilly
Novartis
Sanofi
Horizon Pharma
Abbott
Mylan
Daiichi Sankyo
TEVA
Almatica Pharma
Astellas Pharma
Tide Pharmaceutical
Iroko Pharmaceuticals
Hengrui Pharmaceutical
Abiogen Pharma

The study objectives are:
To analyze and research the global Medicine for Osteoarthritis Pain status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Medicine for Osteoarthritis Pain manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Medicine for Osteoarthritis Pain are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Medicine for Osteoarthritis Pain Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Medicine for Osteoarthritis Pain Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Oral
1.3.3 Injection
1.3.4 External
1.4 Market Segment by Application
1.4.1 Global Medicine for Osteoarthritis Pain Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Medical Care
1.4.3 Personal Care
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Medicine for Osteoarthritis Pain Revenue (2015-2026)
2.1.1 Global Medicine for Osteoarthritis Pain Revenue (2015-2026)
2.1.2 Global Medicine for Osteoarthritis Pain Sales (2015-2026)
2.2 Medicine for Osteoarthritis Pain Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Medicine for Osteoarthritis Pain Sales by Regions (2015-2020)
2.2.2 Global Medicine for Osteoarthritis Pain Revenue by Regions (2015-2020)
2.3 Global Top Medicine for Osteoarthritis Pain Regions (Countries) Ranking by Market Size
2.4 Medicine for Osteoarthritis Pain Industry Trends
2.4.1 Medicine for Osteoarthritis Pain Market Top Trends
2.4.2 Market Drivers
2.4.3 Medicine for Osteoarthritis Pain Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Medicine for Osteoarthritis Pain Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Medicine for Osteoarthritis Pain Manufacturers by Sales (2015-2020)
3.1.1 Global Medicine for Osteoarthritis Pain Sales by Manufacturers (2015-2020)
3.1.2 Global Medicine for Osteoarthritis Pain Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Medicine for Osteoarthritis Pain Sales in 2019
3.2 Global Top Manufacturers Medicine for Osteoarthritis Pain by Revenue
3.2.1 Global Medicine for Osteoarthritis Pain Revenue by Manufacturers (2015-2020)
3.2.2 Global Medicine for Osteoarthritis Pain Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Medicine for Osteoarthritis Pain Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Medicine for Osteoarthritis Pain as of 2019)
3.4 Global Medicine for Osteoarthritis Pain Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Medicine for Osteoarthritis Pain Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Medicine for Osteoarthritis Pain Market
3.7 Key Manufacturers Medicine for Osteoarthritis Pain Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Medicine for Osteoarthritis Pain Historic Market Review by Type (2015-2020)
4.1.2 Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2015-2020)
4.1.3 Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2015-2020)
4.1.4 Medicine for Osteoarthritis Pain Price by Type (2015-2020)
4.1 Global Medicine for Osteoarthritis Pain Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Medicine for Osteoarthritis Pain Sales Forecast by Type (2021-2026)
4.2.3 Global Medicine for Osteoarthritis Pain Revenue Forecast by Type (2021-2026)
4.2.4 Medicine for Osteoarthritis Pain Price Forecast by Type (2021-2026)

5 Global Medicine for Osteoarthritis Pain Market Size by Application
5.1 Global Medicine for Osteoarthritis Pain Historic Market Review by Application (2015-2020)
5.1.2 Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2015-2020)
5.1.3 Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2015-2020)
5.1.4 Medicine for Osteoarthritis Pain Price by Application (2015-2020)
5.2 Global Medicine for Osteoarthritis Pain Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Medicine for Osteoarthritis Pain Sales Forecast by Application (2021-2026)
5.2.3 Global Medicine for Osteoarthritis Pain Revenue Forecast by Application (2021-2026)
5.2.4 Medicine for Osteoarthritis Pain Price Forecast by Application (2021-2026)

6 North America
6.1 North America Medicine for Osteoarthritis Pain Breakdown Data by Company
6.2 North America Medicine for Osteoarthritis Pain Breakdown Data by Type
6.3 North America Medicine for Osteoarthritis Pain Breakdown Data by Application
6.4 North America Medicine for Osteoarthritis Pain Breakdown Data by Countries
6.4.1 North America Medicine for Osteoarthritis Pain Sales by Countries
6.4.2 North America Medicine for Osteoarthritis Pain Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Medicine for Osteoarthritis Pain Breakdown Data by Company
7.2 Europe Medicine for Osteoarthritis Pain Breakdown Data by Type
7.3 Europe Medicine for Osteoarthritis Pain Breakdown Data by Application
7.4 Europe Medicine for Osteoarthritis Pain Breakdown Data by Countries
7.4.1 Europe Medicine for Osteoarthritis Pain Sales by Countries
7.4.2 Europe Medicine for Osteoarthritis Pain Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Medicine for Osteoarthritis Pain Breakdown Data by Company
8.2 Asia Pacific Medicine for Osteoarthritis Pain Breakdown Data by Type
8.3 Asia Pacific Medicine for Osteoarthritis Pain Breakdown Data by Application
8.4 Asia Pacific Medicine for Osteoarthritis Pain Breakdown Data by Regions
8.4.1 Asia Pacific Medicine for Osteoarthritis Pain Sales by Regions
8.4.2 Asia Pacific Medicine for Osteoarthritis Pain Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Medicine for Osteoarthritis Pain Breakdown Data by Company
9.2 Latin America Medicine for Osteoarthritis Pain Breakdown Data by Type
9.3 Latin America Medicine for Osteoarthritis Pain Breakdown Data by Application
9.4 Latin America Medicine for Osteoarthritis Pain Breakdown Data by Countries
9.4.1 Latin America Medicine for Osteoarthritis Pain Sales by Countries
9.4.2 Latin America Medicine for Osteoarthritis Pain Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Medicine for Osteoarthritis Pain Breakdown Data by Type
10.2 Middle East and Africa Medicine for Osteoarthritis Pain Breakdown Data by Application
10.3 Middle East and Africa Medicine for Osteoarthritis Pain Breakdown Data by Countries
10.3.1 Middle East and Africa Medicine for Osteoarthritis Pain Sales by Countries
10.3.2 Middle East and Africa Medicine for Osteoarthritis Pain Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Pfizer Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Pfizer Medicine for Osteoarthritis Pain Products and Services
11.1.5 Pfizer SWOT Analysis
11.1.6 Pfizer Recent Developments
11.2 Johnson and Johnson
11.2.1 Johnson and Johnson Corporation Information
11.2.2 Johnson and Johnson Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Johnson and Johnson Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Johnson and Johnson Medicine for Osteoarthritis Pain Products and Services
11.2.5 Johnson and Johnson SWOT Analysis
11.2.6 Johnson and Johnson Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Business Overview and Total Revenue (2019 VS 2018)
11.3.3 GlaxoSmithKline Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline Medicine for Osteoarthritis Pain Products and Services
11.3.5 GlaxoSmithKline SWOT Analysis
11.3.6 GlaxoSmithKline Recent Developments
11.4 Bayer
11.4.1 Bayer Corporation Information
11.4.2 Bayer Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Bayer Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Bayer Medicine for Osteoarthritis Pain Products and Services
11.4.5 Bayer SWOT Analysis
11.4.6 Bayer Recent Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Corporation Information
11.5.2 Eli Lilly Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Eli Lilly Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Eli Lilly Medicine for Osteoarthritis Pain Products and Services
11.5.5 Eli Lilly SWOT Analysis
11.5.6 Eli Lilly Recent Developments
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Novartis Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Novartis Medicine for Osteoarthritis Pain Products and Services
11.6.5 Novartis SWOT Analysis
11.6.6 Novartis Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Sanofi Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Sanofi Medicine for Osteoarthritis Pain Products and Services
11.7.5 Sanofi SWOT Analysis
11.7.6 Sanofi Recent Developments
11.8 Horizon Pharma
11.8.1 Horizon Pharma Corporation Information
11.8.2 Horizon Pharma Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Horizon Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Horizon Pharma Medicine for Osteoarthritis Pain Products and Services
11.8.5 Horizon Pharma SWOT Analysis
11.8.6 Horizon Pharma Recent Developments
11.9 Abbott
11.9.1 Abbott Corporation Information
11.9.2 Abbott Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Abbott Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Abbott Medicine for Osteoarthritis Pain Products and Services
11.9.5 Abbott SWOT Analysis
11.9.6 Abbott Recent Developments
11.10 Mylan
11.10.1 Mylan Corporation Information
11.10.2 Mylan Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Mylan Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Mylan Medicine for Osteoarthritis Pain Products and Services
11.10.5 Mylan SWOT Analysis
11.10.6 Mylan Recent Developments
11.11 Daiichi Sankyo
11.11.1 Daiichi Sankyo Corporation Information
11.11.2 Daiichi Sankyo Business Overview and Total Revenue (2019 VS 2018)
11.11.3 Daiichi Sankyo Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 Daiichi Sankyo Medicine for Osteoarthritis Pain Products and Services
11.11.5 Daiichi Sankyo SWOT Analysis
11.11.6 Daiichi Sankyo Recent Developments
11.12 TEVA
11.12.1 TEVA Corporation Information
11.12.2 TEVA Business Overview and Total Revenue (2019 VS 2018)
11.12.3 TEVA Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 TEVA Medicine for Osteoarthritis Pain Products and Services
11.12.5 TEVA SWOT Analysis
11.12.6 TEVA Recent Developments
11.13 Almatica Pharma
11.13.1 Almatica Pharma Corporation Information
11.13.2 Almatica Pharma Business Overview and Total Revenue (2019 VS 2018)
11.13.3 Almatica Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 Almatica Pharma Medicine for Osteoarthritis Pain Products and Services
11.13.5 Almatica Pharma SWOT Analysis
11.13.6 Almatica Pharma Recent Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Corporation Information
11.14.2 Astellas Pharma Business Overview and Total Revenue (2019 VS 2018)
11.14.3 Astellas Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.14.4 Astellas Pharma Medicine for Osteoarthritis Pain Products and Services
11.14.5 Astellas Pharma SWOT Analysis
11.14.6 Astellas Pharma Recent Developments
11.15 Tide Pharmaceutical
11.15.1 Tide Pharmaceutical Corporation Information
11.15.2 Tide Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.15.3 Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.15.4 Tide Pharmaceutical Medicine for Osteoarthritis Pain Products and Services
11.15.5 Tide Pharmaceutical SWOT Analysis
11.15.6 Tide Pharmaceutical Recent Developments
11.16 Iroko Pharmaceuticals
11.16.1 Iroko Pharmaceuticals Corporation Information
11.16.2 Iroko Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.16.3 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.16.4 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Products and Services
11.16.5 Iroko Pharmaceuticals SWOT Analysis
11.16.6 Iroko Pharmaceuticals Recent Developments
11.17 Hengrui Pharmaceutical
11.17.1 Hengrui Pharmaceutical Corporation Information
11.17.2 Hengrui Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.17.3 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.17.4 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Products and Services
11.17.5 Hengrui Pharmaceutical SWOT Analysis
11.17.6 Hengrui Pharmaceutical Recent Developments
11.18 Abiogen Pharma
11.18.1 Abiogen Pharma Corporation Information
11.18.2 Abiogen Pharma Business Overview and Total Revenue (2019 VS 2018)
11.18.3 Abiogen Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.18.4 Abiogen Pharma Medicine for Osteoarthritis Pain Products and Services
11.18.5 Abiogen Pharma SWOT Analysis
11.18.6 Abiogen Pharma Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Medicine for Osteoarthritis Pain Sales Channels
12.2.2 Medicine for Osteoarthritis Pain Distributors
12.3 Medicine for Osteoarthritis Pain Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.1.1 Global Medicine for Osteoarthritis Pain Sales Forecast by Regions (2021-2026)
13.1.2 Global Medicine for Osteoarthritis Pain Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.2.2 North America Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.2.3 North America Medicine for Osteoarthritis Pain Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.3.2 Europe Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.3.3 Europe Medicine for Osteoarthritis Pain Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.4.2 Asia Pacific Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Medicine for Osteoarthritis Pain Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.5.2 Latin America Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.5.3 Latin America Medicine for Osteoarthritis Pain Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Medicine for Osteoarthritis Pain Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Medicine for Osteoarthritis Pain Key Market Segments
Table 2. Ranking of Global Top Medicine for Osteoarthritis Pain Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Medicine for Osteoarthritis Pain Market Size Growth Rate by Type 2021-2026 (K Units) & (Million US$)
Table 4. Major Manufacturers of Oral
Table 5. Major Manufacturers of Injection
Table 6. Major Manufacturers of External
Table 7. Global Medicine for Osteoarthritis Pain Market Share by Application 2019-2025 (K Units)
Table 8. Global Medicine for Osteoarthritis Pain Market Size by Regions 2015-2020 (K Units) & (Million US$)
Table 9. Global Medicine for Osteoarthritis Pain Sales by Regions 2015-2020 (K Units)
Table 10. Global Medicine for Osteoarthritis Pain Sales Market Share by Regions 2015-2020
Table 11. Global Medicine for Osteoarthritis Pain Revenue by Regions 2015-2020 (Million US$)
Table 12. Global Medicine for Osteoarthritis Pain Revenue Market Share by Regions 2015-2020
Table 13. Top Medicine for Osteoarthritis Pain Regions (Countries) Ranking by Market Size (US$ Million) in 2019
Table 14. Market Top Trends
Table 15. Medicine for Osteoarthritis Pain Key Drivers: Impact Analysis (2021-2026)
Table 16. Medicine for Osteoarthritis Pain Key Challenges
Table 17. Main Points Interviewed from Key Medicine for Osteoarthritis Pain Players: Views for Future
Table 18. Global Medicine for Osteoarthritis Pain Sales by Manufacturers (2015-2020) (K Units)
Table 19. Global Medicine for Osteoarthritis Pain Sales Share by Manufacturers (2015-2020)
Table 20. Medicine for Osteoarthritis Pain Revenue by Manufacturers (2015-2020) (Million US$)
Table 21. Medicine for Osteoarthritis Pain Revenue Share by Manufacturers (2015-2020)
Table 22. Global Medicine for Osteoarthritis Pain Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Medicine for Osteoarthritis Pain as of 2019)
Table 24. Key Manufacturers Medicine for Osteoarthritis Pain Average Selling Price (ASP) (2015-2020) (USD/Unit)
Table 25. Key Manufacturers Medicine for Osteoarthritis Pain Plants/Factories Distribution
Table 26. Key Manufacturers Medicine for Osteoarthritis Pain Area Served
Table 27. Date of Key Manufacturers Enter into Medicine for Osteoarthritis Pain Market
Table 28. Key Manufacturers Medicine for Osteoarthritis Pain Product Type
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Oral Sales and Revenue (2015-2020) (K Units) & (Million US$)
Table 31. Global Injection Sales and Revenue (2015-2020) (K Units) & (Million US$)
Table 32. Global External Sales ana Revenue (2015-2020) (K Units) & (Million US$)
Table 33. Global Medicine for Osteoarthritis Pain Sales (K Units) by Type (2015-2020)
Table 34. Global Medicine for Osteoarthritis Pain Sales Share by Type (2015-2020)
Table 35. Global Medicine for Osteoarthritis Pain Revenue (US$ Million) Market Share by Type (2015-2020)
Table 36. Global Medicine for Osteoarthritis Pain Price (K Units) by Type (2015-2020)
Table 37. Global Medicine for Osteoarthritis Pain Sales (K Units) by Type (2021-2026)
Table 38. Global Medicine for Osteoarthritis Pain Sales Share by Type (2021-2026)
Table 39. Global Medicine for Osteoarthritis Pain Revenue (US$ Million) Market Share by Type (2021-2026)
Table 40. Global Medicine for Osteoarthritis Pain Revenue Share by Type (2021-2026)
Table 41. Global Medicine for Osteoarthritis Pain Price (K Units) by Type (2021-2026)
Table 42. Global Medicine for Osteoarthritis Pain Sales (K Units) by Application (2015-2020)
Table 43. Global Medicine for Osteoarthritis Pain Sales Share by Application (2015-2020)
Table 44. Global Medicine for Osteoarthritis Pain Revenue (US$ Million) Market Share by Application (2015-2020)
Table 45. Global Medicine for Osteoarthritis Pain Price by Application 2015-2020 (USD/Unit)
Table 46. Global Medicine for Osteoarthritis Pain Sales by Application (2015-2020) (K Units)
Table 47. Global Medicine for Osteoarthritis Pain Sales Share by Application (2015-2020)
Table 48. Global Medicine for Osteoarthritis Pain Revenue (US$ Million) Market Share by Application (2021-2026)
Table 49. Global Medicine for Osteoarthritis Pain Revenue Share by Application (2021-2026)
Table 50. Global Medicine for Osteoarthritis Pain Price (K Units) by Application (2021-2026)
Table 51. North America Medicine for Osteoarthritis Pain Sales by Company (2015-2020) (K Units)
Table 52. North America Medicine for Osteoarthritis Pain Sales Market Share by Company (2015-2020)
Table 53. North America Medicine for Osteoarthritis Pain Sales by Type (2015-2020) (K Units)
Table 54. North America Medicine for Osteoarthritis Pain Sales Market Share by Type (2015-2020)
Table 55. North America Medicine for Osteoarthritis Pain Sales by Application (2015-2020) (K Units)
Table 56. North America Medicine for Osteoarthritis Pain Sales Market Share by Application (2015-2020)
Table 57. North America Medicine for Osteoarthritis Pain Sales by Countries (2015-2020) (K Units)
Table 58. North America Medicine for Osteoarthritis Pain Sales Market Share by Countries (2015-2020)
Table 59. North America Medicine for Osteoarthritis Pain Revenue by Countries (2015-2020) (Million US$)
Table 60. North America Medicine for Osteoarthritis Pain Revenue Market Share by Countries (2015-2020)
Table 61. Europe Medicine for Osteoarthritis Pain Sales by Company (2015-2020) (K Units)
Table 62. Europe Medicine for Osteoarthritis Pain Sales Market Share by Company (2015-2020)
Table 63. Europe Medicine for Osteoarthritis Pain Sales by Type (2015-2020) (K Units)
Table 64. Europe Medicine for Osteoarthritis Pain Sales Market Share by Type (2015-2020)
Table 65. Europe Medicine for Osteoarthritis Pain Sales by Application (2015-2020) (K Units)
Table 66. Europe Medicine for Osteoarthritis Pain Sales Market Share by Application (2015-2020)
Table 67. Europe Medicine for Osteoarthritis Pain Sales by Countries (2015-2020) (K Units)
Table 68. Europe Medicine for Osteoarthritis Pain Sales Market Share by Countries (2015-2020)
Table 69. Europe Medicine for Osteoarthritis Pain Revenue by Countries (2015-2020) (Million US$)
Table 70. Europe Medicine for Osteoarthritis Pain Revenue Market Share by Countries (2015-2020)
Table 71. Asia Pacific Medicine for Osteoarthritis Pain Sales by Regions (2015-2020) (K Units)
Table 72. Asia Pacific Medicine for Osteoarthritis Pain Sales Market Share by Regions (2015-2020)
Table 73. Asia Pacific Medicine for Osteoarthritis Pain Sales by Type (2015-2020) (K Units)
Table 74. Asia Pacific Medicine for Osteoarthritis Pain Sales Market Share by Type (2015-2020)
Table 75. Asia Pacific Medicine for Osteoarthritis Pain Sales by Application (2015-2020) (K Units)
Table 76. Asia Pacific Medicine for Osteoarthritis Pain Sales Market Share by Application (2015-2020)
Table 77. Asia Pacific Medicine for Osteoarthritis Pain Sales by Countries (2015-2020) (K Units)
Table 78. Asia Pacific Medicine for Osteoarthritis Pain Sales Market Share by Regions (2015-2020)
Table 79. Asia Pacific Medicine for Osteoarthritis Pain Revenue by Regions (2015-2020) (Million US$)
Table 80. Asia Pacific Medicine for Osteoarthritis Pain Revenue Market Share by Regions (2015-2020)
Table 81. Latin America Medicine for Osteoarthritis Pain Sales by Company (2015-2020) (K Units)
Table 82. Latin America Medicine for Osteoarthritis Pain Sales Market Share by Company (2015-2020)
Table 83. Latin America Medicine for Osteoarthritis Pain Sales by Type (2015-2020) (K Units)
Table 84. Latin America Medicine for Osteoarthritis Pain Sales Market Share by Type (2015-2020)
Table 85. Latin America Medicine for Osteoarthritis Pain Sales by Application (2015-2020) (K Units)
Table 86. Latin America Medicine for Osteoarthritis Pain Sales Market Share by Application (2015-2020)
Table 87. Latin America Medicine for Osteoarthritis Pain Sales by Countries (2015-2020) (K Units)
Table 88. Latin America Medicine for Osteoarthritis Pain Sales Market Share by Countries (2015-2020)
Table 89. Latin America Medicine for Osteoarthritis Pain Revenue by Countries (2015-2020) (Million US$)
Table 90. Latin America Medicine for Osteoarthritis Pain Revenue Market Share by Countries (2015-2020)
Table 91. Middle East and Africa Medicine for Osteoarthritis Pain Sales by Type (2015-2020) (K Units)
Table 92. Middle East and Africa Medicine for Osteoarthritis Pain Sales Market Share by Type (2015-2020)
Table 93. Middle East and Africa Medicine for Osteoarthritis Pain Sales by Application (2015-2020) (K Units)
Table 94. Middle East and Africa Medicine for Osteoarthritis Pain Sales Market Share by Application (2015-2020)
Table 95. Middle East and Africa Medicine for Osteoarthritis Pain Sales by Countries (2015-2020) (K Units)
Table 96. Middle East and Africa Medicine for Osteoarthritis Pain Sales Market Share by Countries (2015-2020)
Table 97. Middle East and Africa Medicine for Osteoarthritis Pain Revenue by Countries (2015-2020) (Million US$)
Table 98. Middle East and Africa Medicine for Osteoarthritis Pain Revenue Market Share by Countries (2015-2020)
Table 99. Pfizer Company Details
Table 100. Pfizer Description and Business Overview
Table 101. Pfizer Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 102. Pfizer Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 103. Pfizer Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 104. Pfizer Recent Development
Table 105. Johnson and Johnson Company Details
Table 106. Johnson and Johnson Description and Business Overview
Table 107. Johnson and Johnson Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Johnson and Johnson Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 109. Johnson and Johnson Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 110. Johnson and Johnson Recent Development
Table 111. GlaxoSmithKline Company Details
Table 112. GlaxoSmithKline Description and Business Overview
Table 113. GlaxoSmithKline Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. GlaxoSmithKline Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 115. GlaxoSmithKline Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 116. GlaxoSmithKline Recent Development
Table 117. Bayer Company Details
Table 118. Bayer Description and Business Overview
Table 119. Bayer Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Bayer Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 121. Bayer Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 122. Bayer Recent Development
Table 123. Eli Lilly Company Details
Table 124. Eli Lilly Description and Business Overview
Table 125. Eli Lilly Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 126. Eli Lilly Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 127. Eli Lilly Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 128. Eli Lilly Recent Development
Table 129. Novartis Company Details
Table 130. Novartis Description and Business Overview
Table 131. Novartis Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 132. Novartis Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 133. Novartis Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 134. Novartis Recent Development
Table 135. Sanofi Company Details
Table 136. Sanofi Description and Business Overview
Table 137. Sanofi Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 138. Sanofi Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 139. Sanofi Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 140. Sanofi Recent Development
Table 141. Horizon Pharma Company Details
Table 142. Horizon Pharma Description and Business Overview
Table 143. Horizon Pharma Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 144. Horizon Pharma Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 145. Horizon Pharma Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 146. Horizon Pharma Recent Development
Table 147. Abbott Company Details
Table 148. Abbott Description and Business Overview
Table 149. Abbott Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 150. Abbott Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 151. Abbott Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 152. Abbott Recent Development
Table 153. Mylan Company Details
Table 154. Mylan Description and Business Overview
Table 155. Mylan Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 156. Mylan Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 157. Mylan Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 158. Mylan Recent Development
Table 159. Daiichi Sankyo Company Details
Table 160. Daiichi Sankyo Description and Business Overview
Table 161. Daiichi Sankyo Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 162. Daiichi Sankyo Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 163. Daiichi Sankyo Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 164. Daiichi Sankyo Recent Development
Table 165. TEVA Company Details
Table 166. TEVA Description and Business Overview
Table 167. TEVA Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 168. TEVA Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 169. TEVA Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 170. TEVA Recent Development
Table 171. Almatica Pharma Company Details
Table 172. Almatica Pharma Description and Business Overview
Table 173. Almatica Pharma Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 174. Almatica Pharma Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 175. Almatica Pharma Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 176. Almatica Pharma Recent Development
Table 177. Astellas Pharma Company Details
Table 178. Astellas Pharma Description and Business Overview
Table 179. Astellas Pharma Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 180. Astellas Pharma Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 181. Astellas Pharma Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 182. Astellas Pharma Recent Development
Table 183. Tide Pharmaceutical Company Details
Table 184. Tide Pharmaceutical Description and Business Overview
Table 185. Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 186. Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 187. Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 188. Tide Pharmaceutical Recent Development
Table 189. Iroko Pharmaceuticals Company Details
Table 190. Iroko Pharmaceuticals Description and Business Overview
Table 191. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 192. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 193. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 194. Iroko Pharmaceuticals Recent Development
Table 195. Hengrui Pharmaceutical Company Details
Table 196. Hengrui Pharmaceutical Description and Business Overview
Table 197. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 198. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 199. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 200. Hengrui Pharmaceutical Recent Development
Table 201. Abiogen Pharma Company Details
Table 202. Abiogen Pharma Description and Business Overview
Table 203. Abiogen Pharma Medicine for Osteoarthritis Pain Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 204. Abiogen Pharma Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020)
Table 205. Abiogen Pharma Medicine for Osteoarthritis Pain Sales Market Share in Global Market
Table 206. Abiogen Pharma Recent Development
Table 207. Medicine for Osteoarthritis Pain Distributors List
Table 208. Medicine for Osteoarthritis Pain Customers List
Table 209. Global Medicine for Osteoarthritis Pain Sales Forecast 2021-2026 (K Units) & (Million US$)
Table 210. Global Medicine for Osteoarthritis Pain Sales Forecast by Type 2021-2026 (K Units)
Table 211. Global Medicine for Osteoarthritis Pain Sales Forecast by Application 2021-2026 (K Units)
Table 212. Global Medicine for Osteoarthritis Pain Sales Forecast by Regions 2021-2026 (K Units)
Table 213. Global Medicine for Osteoarthritis Pain Revenue Forecast by Regions 2021-2026 (Million US$)
Table 214. North America Medicine for Osteoarthritis Pain Sales Forecast by Countries 2021-2026 (K Units)
Table 215. North America Medicine for Osteoarthritis Pain Revenue Forecast by Countries 2021-2026
Table 216. Europe Medicine for Osteoarthritis Pain Sales Forecast by Countries 2021-2026 (K Units)
Table 217. Europe Medicine for Osteoarthritis Pain Revenue Market Share Forecast by Countries 2021-2026
Table 218. Asia Pacific Medicine for Osteoarthritis Pain Sales Forecast by Regions 2021-2026 (K Units)
Table 219. Asia Pacific Medicine for Osteoarthritis Pain Revenue Forecast by Regions 2021-2026 (Million US$)
Table 220. Latin America Medicine for Osteoarthritis Pain Sales Forecast by Countries 2021-2026 (K Units)
Table 221. Latin America Medicine for Osteoarthritis Pain Revenue Forecast by Countries 2021-2026 (Million US$)
Table 222. Middle East and Africa Medicine for Osteoarthritis Pain Sales Forecast by Regions 2021-2026 (K Units)
Table 223. Middle East and Africa Medicine for Osteoarthritis Pain Revenue Forecast by Regions 2021-2026 (Million US$)
Table 224. Research Programs/Design for This Report
Table 225. Key Data Information from Secondary Sources
Table 226. Key Data Information from Primary Sources
List of Figures
Figure 1. Medicine for Osteoarthritis Pain Product Picture
Figure 2. Global Medicine for Osteoarthritis Pain Sales Market Shar by Type 2015-2026
Figure 3. Oral Figures
Figure 4. Injection Figures
Figure 5. External Figures
Figure 6. Global Medicine for Osteoarthritis Pain Sales Market Share by Application in 2019 & 2026
Figure 7. Medical Care Use Case
Figure 8. Personal Care Use Case
Figure 9. Medicine for Osteoarthritis Pain Report Years Considered
Figure 10. Global Medicine for Osteoarthritis Pain Market Size 2015-2026 (Million US$)
Figure 11. Global Medicine for Osteoarthritis Pain Sales 2015-2020 (K Units)
Figure 12. Global Medicine for Osteoarthritis Pain Market Size Market Share by Regions 2015-2020
Figure 13. Global Medicine for Osteoarthritis Pain Sales Market Share by Regions in 2019
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Medicine for Osteoarthritis Pain Sales Share by Manufacturers in 2019
Figure 16. The 5 and 10 Largest Manufacturers in the World: Market Share by Medicine for Osteoarthritis Pain Sales in 2019
Figure 17. Medicine for Osteoarthritis Pain Value Share by Manufacturers in 2019
Figure 18. Medicine for Osteoarthritis Pain Revenue Share by Manufacturers In 2019
Figure 19. Medicine for Osteoarthritis Pain Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Medicine for Osteoarthritis Pain Revenue Share by Type (2015-2020)
Figure 21. Global Medicine for Osteoarthritis Pain Revenue Growth Rate by Type in 2015 & 2019
Figure 22. Global Medicine for Osteoarthritis Pain Market Share by Price Range (2015-2020)
Figure 23. Global Medicine for Osteoarthritis Pain Revenue Share by Application (2015-2020)
Figure 24. Global Medicine for Osteoarthritis Pain Revenue Growth Rate by Application in 2015 & 2019
Figure 25. North America Medicine for Osteoarthritis Pain Revenue Growth Rate 2015-2020 (Million US$)
Figure 26. U.S. Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 27. Canada Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 28. Europe Medicine for Osteoarthritis Pain Revenue Growth Rate 2015-2020 (Million US$)
Figure 29. Germany Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 30. France Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 31. U.K. Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 32. Italy Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 33. Russia Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 34. Asia Pacific Medicine for Osteoarthritis Pain Revenue Growth Rate 2015-2020 (Million US$)
Figure 35. China Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 36. Japan Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 37. South Korea Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 38. India Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 39. Australia Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 40. Taiwan Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 41. Indonesia Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 42. Thailand Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 43. Malaysia Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 44. Philippines Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 45. Vietnam Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 46. Latin America Medicine for Osteoarthritis Pain Revenue Growth Rate 2015-2020 (Million US$)
Figure 47. Mexico Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 48. Brazil Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 49. Argentina Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 50. Middle East and Africa Medicine for Osteoarthritis Pain Revenue Growth Rate 2015-2020 (Million US$)
Figure 51. Turkey Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 52. Saudi Arabia Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 53. U.A.E Medicine for Osteoarthritis Pain Sales Growth Rate (2015-2020) (K Units)
Figure 54. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Johnson and Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Horizon Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Abbott Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Daiichi Sankyo Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. TEVA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Almatica Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Astellas Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Tide Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. Iroko Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 70. Hengrui Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 71. Abiogen Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 72. Medicine for Osteoarthritis Pain Value Chain
Figure 73. Channels of Distribution
Figure 74. Distributors Profiles
Figure 75. North America Medicine for Osteoarthritis Pain Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 76. North America Medicine for Osteoarthritis Pain Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 77. Europe Medicine for Osteoarthritis Pain Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 78. Europe Medicine for Osteoarthritis Pain Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 79. Asia Pacific Medicine for Osteoarthritis Pain Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 80. Asia Pacific Medicine for Osteoarthritis Pain Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 81. Latin America Medicine for Osteoarthritis Pain Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 82. Latin America Medicine for Osteoarthritis Pain Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 83. Middle East and Africa Medicine for Osteoarthritis Pain Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 84. Middle East and Africa Medicine for Osteoarthritis Pain Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed


【掲載企業】

Pfizer、Johnson and Johnson、GlaxoSmithKline、Bayer、Eli Lilly、Novartis、Sanofi、Horizon Pharma、Abbott、Mylan、Daiichi Sankyo、TEVA、Almatica Pharma、Astellas Pharma、Tide Pharmaceutical、Iroko Pharmaceuticals、Hengrui Pharmaceutical、Abiogen Pharma

★調査レポート[世界の変形性関節痛用薬市場:成長動向・競争分析2020-2026] (コード:QYR20AP01436)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の変形性関節痛用薬市場:成長動向・競争分析2020-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆